Pharmabiz4d
US FDA grants breakthrough therapy designation to Innate Pharma’s lacutamab for relapsed or refractory Sézary syndrome
US FDA grants breakthrough therapy designation to Innate Pharma’s lacutamab for relapsed or refractory Sézary syndrome: Marseille, France Tuesday, February 18, 2025, 12:00 Hrs ...
Le Lézard5d
Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to ...
Business Wire6d
Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome
Mycosis fungoides, and Sézary syndrome, its leukemic variant, are the most common CTCL subtypes. The overall 5-year survival rate, which depends in part on disease subtype, is approximately 10% ...
GlobalData on MSN5d
Innate’s lacutamab gains FDA breakthrough therapy designation
Innate Pharma has secured US Food and Drug Administration (FDA) breakthrough therapy designation for lacutamab to treat ...
Original paper19d
Psychosocial burden of patients with mycosis fungoides and Sézary syndrome compared to other dermatological patients. Pilot study
Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. French Study Group of Cutaneous Lymphomas. Blood 2000; 95: 2212-8. 3. Olsen EA, Rook AH, Zic J, et al.
Oncology Nurse Advisor9d
CD70-Directed CAR-T Therapy Shows Promise in T-Cell Lymphoma
Researchers sought to determine whether the CAR-T therapy volamcabtagene durzigedleucel (CTX130) would be effective in patients with T-cell lymphoma.
Mena FN24d
Global Poteligeo Market Forecast 2025-2034: Analyzing Growth Drivers, Market Share, Segments, And Emerging Trends
This monoclonal antibody targets CCR4-positive malignant T-cells found in cutaneous T-cell lymphoma types and is approved for treating adult patients with relapsed or refractory mycosis fungoides ...